Malta - inglese - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cytarabine - solution for infusion or injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cytarabine - solution for infusion or injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cytarabine - solution for infusion or injection - cytarabine 100 mg/ml - antineoplastic agents

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 2 g - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa212) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Malta - inglese - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents